A pilot study to evaluate efficacy and safety of resveratrol for muscular dystrophy.

A pilot study to evaluate efficacy and safety of resveratrol for muscular dystrophy. - A pilot study of resveratrol for muscular dystrophy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014836

Enrollment

Registered

2014-08-12

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy, Becker muscular dystrophy, Fukuyama congenital muscular dystrophy

Interventions

500mg resveratrol is administrated daily for 8 weeks. Subsequently, resveratrol is increased to 1500mg by 500mg every 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed with Duchenne, Becker or Fukuyama Type muscular dystrophy by clinical feature, muscular biopsy and/or genetic test. 2) 12 years of age or older. 3) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Hypersensitivity to resveratrol. 2) Disqualified for trial by principal investigator.

Design outcomes

Primary

Measure	Time frame
Muscular strength, motor function and muscular injury marker befor and after adoministratation of resveratrol.	—

Secondary

Measure	Time frame
Advers events.	—

Countries

Japan

Contacts

Public ContactKentaro Kawamura

Sapporo Medical University Department of Pediatrics

k.kawamura@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026